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Summary
In a randomised controlled trial of vitamin D during pregnancy, we demonstrated that women with 
lower self-efficacy were more likely to experience practical problems with taking the trial 
medication, and that this was associated with lower compliance and achieved 25(OH)-vitamin D 
concentrations.
Purpose—The relationship between self-efficacy (the belief that one can carry out a behaviour), 
compliance with study protocol and outcome was explored within a randomised, double-blind, 
placebo-controlled trial of vitamin D supplementation in pregnancy.
Methods—In the MAVIDOS trial, women with circulating plasma 25(OH)-vitamin D of 
25-100nmol/l in early pregnancy were randomised to either 1000IU cholecalciferol/day or 
matched placebo from 14 weeks until delivery. Circulating 25(OH)-vitamin D concentrations were 
assessed at 14 and 34 weeks’ gestation. A sequential sub-sample completed Schwarzer’s General 
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Self-Efficacy Scale at 14 and 34 weeks and the Problematic Experiences of Therapy Scale at 34 
weeks. Women were interviewed about their experiences of the trial, and interview transcripts 
analysed thematically.
Results—In 203 women, those with higher self-efficacy were less likely to experience practical 
problems taking the study medication (OR 0.81(95%CI 0.69, 0.95), p = 0.01). Over half reported 
practical problems associated with poorer compliance with the protocol requiring women to take 
the medication daily. Compliance in women who experienced practical problems was 94% 
compared with 98% for those with no problems, (p < 0.001). Poorer compliance was also 
associated with lower concentrations of 25(OH)-D in late pregnancy in the treatment group 
(β=0.54nmol/l (95%CI 0.18,0.89), p =0.003). Thematic analysis suggested common difficulties 
were remembering to take the medication every day and swallowing the large capsules.
Conclusions—These findings suggest that differences in self-efficacy influence trial outcomes. 
Such information may help clinicians anticipate responses to routine vitamin D supplementation in 
pregnancy and identify those who may need more support to comply.
Trial registration—ISRCTN82927713, registered 11/04/2008
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Introduction
There is growing evidence that early growth and factors operating in utero or early infancy 
influence peak bone mass in adulthood, a known risk factor for osteoporosis.[1] A large, 
recent, population-based trial of vitamin D supplementation in pregnancy (MAVIDOS) has 
confirmed the efficacy of 1000IU/day cholecalciferol for maternal 25(OH)D repletion. 
Furthermore, although negative for the primary outcome of infant whole body bone mineral 
content by DXA, the trial demonstrated in a pre-specified secondary analysis, a greater than 
0.5 SD increase in infant BMC in neonates born to supplemented compared to placebo 
mothers, and who delivered during the winter months.[2] The implication of these findings 
is that supplementing pregnant women with vitamin D may be an important population-wide 
public health intervention to help prevent osteoporosis. In order for vitamin D 
supplementation in pregnancy to have long-term impact on the prevalence of this disease, 
women have to be prepared to take supplements in sufficient quantity and with sufficient 
consistency that they achieve circulating 25(OH)D repletion throughout gestation. This 
paper describes an investigation of the individual factors that may present barriers to 
compliance with this requirement.
Individual psychological characteristics, such as a sense of self-efficacy (the belief that one 
is capable of carrying out a specific behaviour), are important determinants of behaviour and 
ultimately of health status.[3] Having a higher sense of self-efficacy and hence a greater 
sense of control over life has been shown repeatedly to predict better physical health and 
greater longevity.[4] Self-efficacy has also been shown to mediate the effect of dietary 
interventions on nutrient status and dietary quality.[5] Higher self-efficacy enabled 
participants to respond to a nutrition intervention by increasing their fruit and vegetable 
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consumption, because they believed they were capable of doing so.[6] In the context of the 
vitamin D supplementation trial described above, a participant’s self-efficacy is likely 
therefore to describe her belief that she is able to take the action required by the study 
protocol, which specifies that she should take the study medication every day.[7]
The difficulties of achieving compliance with nutrient supplementation recommendations in 
pregnancy are well documented.[8,9] Factors known to affect compliance with such 
recommendations depend on the population under study, and include age, level of education 
and socio-economic status.[10–12] The most common reasons given for not taking 
supplements during pregnancy are simply forgetting to take them or being put off taking 
them by the side effects.[13,14] Compliance with supplementation regimes appears to be 
better in participants in clinical trials, though there may be features of the way clinical trials 
are run and how they are staffed that affect both compliance with the intervention protocol 
and trial outcomes.[15] Very little is understood, however, about the role played by trial 
participants’ psychological characteristics, and how they may affect compliance with trial 
protocols and hence change trial outcomes.
This paper examines the relationship between women’s self-efficacy and their circulating 
vitamin D concentration in late pregnancy in the context of a supplementation trial. It 
explores factors that may affect compliance with the study protocol and how this might 
affect the trial outcome. Analysis reported in this paper tests the hypothesis that having 
higher self-efficacy is associated with better compliance and with factors affecting 
compliance, which in turn increase women’s vitamin D status at the end of the trial.
Methods
A detailed description of The Maternal Vitamin D Osteoporosis Study (MAVIDOS) has 
been previously published[16]. Briefly, MAVIDOS is a multicentre, double-blind, 
randomised, placebo-controlled, parallel-group trial of vitamin D supplementation in 
pregnancy in the United Kingdom. The study was conducted in accordance with guidelines 
laid down in the Declaration of Helsinki and was approved by the Southampton and South 
West Hampshire Research Ethics Committee. MAVIDOS was registered prospectively 
(ISRCTN:82927713; EUDRACT:2007-001716-23); full approval from UK MHRA was 
granted, and written, informed consent obtained from all participants.
Participants
The MAVIDOS trial was run at three study sites in the UK. Pregnant women were recruited 
when in attendance for early pregnancy ultrasound screening. The participants in the sub-
study reported in this paper were from the sample of 1207 recruited at one of these sites 
[University Hospital Southampton NHS Foundation Trust, Southampton, UK]. Women were 
recruited if they were aged over 18 years, were having a singleton pregnancy, were of a 
gestation less than 17 weeks based on last menstrual period and had 25(OH)D between 25 
and 100nmol/l and serum calcium<2.75mmol/l. Women with known metabolic bone disease, 
renal stones, hyperparathyroidism or hypercalciuria, those taking medication known to 
interfere with fetal growth, with fetal anomalies on ultrasonography and those taking more 
than 400 IU/day vitamin D supplementation were excluded. Eligible women with were 
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recruited and randomised at 14 weeks’ gestation (or as soon as possible before 17 weeks’ 
gestation if recruited later) to either cholecalciferol 1000IU/day or matched placebo taken 
until delivery of the baby. Recruitment to this sub-study began part-way through the trial. A 
further sub-sample of women who had taken part in the trial were written to asking if they 
were prepared to be interviewed about their experience of taking part in the trial . The 
number of interviews was determined by the point at which saturation of topics was reached.
Measures
Biochemical—Reference blood samples were collected from the mother at 14 and 34 
weeks’ gestation, and stored at -80°C after processing. Measurement of plasma 25(OH)-D 
(Liaison RIA automated platform, Diasorin, Minnesota, USA) was undertaken centrally 
(MRC Human Nutrition Research, Cambridge, UK) in a single batch at the end of the study.
Questionnaires—Women self-completed Schwarzer’s General Self-Efficacy Scale at 14 
and 34 weeks of pregnancy. The General Self-efficacy Scale used was a shortened, 5-item 
scale derived from the original 10-item scale, and measured the general sense that one can 
perform novel or difficult tasks, or cope with adversity in various domains of human 
functioning. [17] This shortened version has been used in previous studies of women of 
child-bearing age in the UK, has internal consistency (Cronbach’s alpha statistic = 0.85), 
and has been shown to predict quality of diet.[18] Example items are ‘I can always manage 
to solve difficult problems if I try hard enough’ and ‘I am calm when things are difficult 
because I know I can cope’. Women were asked to indicate on a 4-point scale how much 
they agreed with each item. Responses were coded from 1 (strongly disagree) to 4 (strongly 
agree) and summed to give an overall score. A higher score indicated higher levels of self-
efficacy, with a range of possible scores from 5 to 20. At 34 weeks of pregnancy, women 
also completed a modified version of the Problematic Experiences of Therapy Scale (PETS).
[19] This scale is a brief self-report measure that assesses the extent to which respondents 
perceive that they have been prevented from carrying out an intervention for common and 
plausible reasons. Three of the four sub-scales of this assessment were used and adapted to 
address issues women may have had taking the trial medication. Example scale items used in 
this study are ‘I could not take my capsules because I was unsure how to do it properly’ 
(uncertainty about medication sub-scale), ‘I skipped taking my capsules because I was not 
sure if it was helping’ (doubts about medication sub-scale), and ‘lack of time prevented me 
from taking my capsules’ (practical problems sub-scale). At the end of this questionnaire, 
women were then asked in an additional question how they had found taking the study 
medication and given space to write about their experiences.
At 14 weeks of pregnancy, women were asked about their age, their level of education and 
amount of time spent outdoors, and their weights and heights were measured.[16] 
Compliance with the medication was assessed by pill count at the end of the trial and was 
defined as the percentage of pills taken of the number of pills each woman was expected to 
take. If this information was not available, proportions of pills taken at 19 or 34 weeks was 
used, whichever was the latest count. At the end of the trial, women who consented were 
interviewed at home by a member of the research team about their experiences of taking part 
in the trial and the interview transcripts subjected to a thematic analysis.
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Statistical analysis
This sub-study was carried out in all women who provided data on self-efficacy at 14 weeks 
and had vitamin D data at 34 weeks. Distribution of circulating 25(OH)D at 34 weeks was 
checked to assess normality. Self-efficacy score and compliance were analysed as 
continuous variables. The three scores derived from the PETS, defined as "practical 
problems", "uncertainty about medication" and "doubts about medication" were 
dichotomised into having no problems or having at least one problem. The free text 
responses to the question about how they found taking the study medication were coded into 
one of six types of response: "all fine", "ok, built into daily routine", "occasionally forgot 
tablets", "issue with capsule size", "issue with illness", "forgot for short periods because of 
change in routine".
Analyses were performed separately for intervention and placebo groups, and then for the 
two groups combined. The associations between predictors and 25(OH)D at 34 weeks were 
explored with linear regression. The results are displayed as β-coefficients with 95% 
confidence intervals (95% CI). Logistic regression was used to explore the association 
between self-efficacy and PETS variables describing problems with taking the medication, 
with estimates displayed as ORs (95% CIs). Mediation analyses were conducted to test the 
mediation effect of experiences of taking the study medication on the relationship between 
self-efficacy and 25(OH)D at 34 weeks. The mediation test was conducted according to the 
method proposed by Baron and Kenny.[20] Three regression models were fitted: first, the 
effect of self-efficacy on 25(OH)D at 34 weeks was tested; second, experiences of taking 
study medication (the mediators) were regressed on self-efficacy; and third, 25(OH)D at 34 
weeks was regressed on both the mediators and self-efficacy. The mediation effect test is for 
an attenuation of the association between self-efficacy and 25(OH)D at 34 weeks after 
adjusting for experiences of taking the study medication. Analyses were carried out using 
Stata v 14.0 (Statacorp, College Station, Texas, USA).
Results
A total of 344 women completed the self-efficacy questionnaire at 14 weeks of pregnancy. 
Of those women, 328 provided 25(OH)-vitamin D measurements at 14 weeks and 218 at 34 
weeks. Table 1 provides data on the age of this group of women, and their level of education. 
Mean self-efficacy at 14 weeks, and 25(OH)-vitamin D at 14 and 34 weeks of pregnancy are 
also shown, as are scores on the PETS scale and their percent compliance. The data are 
presented for control and treatment groups separately and for the whole group. The table 
shows that, in this sub-sample there were no differences between groups in these variables 
except in 25(OH)D at 34 weeks. Higher 25(OH)-vitamin D levels in the treatment group 
demonstrate the effectiveness of the intervention and suggest that this group of women was 
compliant with the trial protocol. Compliance with the medication regime was generally 
high, averaging 96% of pills taken during pregnancy. The table also shows, however, that of 
the 203 women who completed the PETS at 34 weeks, over half reported practical problems 
with taking the trial medication whereas fewer reported doubts or uncertainties about the 
medication.
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Table 2 shows that women entering the trial with higher self-efficacy were less likely 
(OR<1) to experience practical problems with taking the study medication, though they did 
not seem to be more likely to have doubts or uncertainties about whether it was right for 
them to be taking it. Neither was their lower self-efficacy associated with poorer compliance 
with the trial protocol.
Experiencing practical problems, having doubts and uncertainties about the medication and 
rate of compliance were all strongly associated with one another (p < 0.05 for all). Women 
who experienced no doubts or uncertainties about taking the medication tended also to have 
no practical problems, and those who experienced no doubts, uncertainties or practical 
problems had higher rates of compliance (Table 3). For women in the treatment group, Table 
4 shows that the more compliant they were, the higher their 25(OH)-vitamin D levels at 34 
weeks. Figure 1 summarises the relationships between self-efficacy, experiences taking the 
study medication and 25(OH)-vitamin D status at 34 weeks. There were no mediation effects 
of experiences of taking study medication on the relationship between self-efficacy at 14 
weeks of pregnancy and vitamin D levels at 34 weeks.
In the combined group of women in both treatment and placebo groups, those who had 
higher self-efficacy on entering the study tended to have higher 25(OH)D status at 14 weeks 
of pregnancy (β = 1.04, 95%CI 0.05,2.03, p=0.04). As Table 4 shows, this was not the case 
by late pregnancy (34 weeks) in either the treatment or placebo groups. Circulating 
25(OH)D levels increased less between 14 and 34 weeks in women with higher self-efficacy 
irrespective of their allocation, possibly because women with higher self-efficacy entered 
pregnancy with higher vitamin D levels (β = -1.73 nmol/l, 95%CI -3.40, -0.07, p = 0.04).
In response to the additional question about how they had found taking the study 
medication, 78% of the women reported no issues or said that they had developed a daily 
routine that helped them to remember to take the medication. A small percentage (11%) said 
they occasionally forgot to take a tablet, and the remainder said that the size of the tablet was 
a problem, or that illness or a change in routine, such as a holiday, had prevented them from 
taking the tablets for a period.
Qualitative interviews with 14 women who had taken part in the trial confirmed that there 
were no major difficulties in complying with the requirement to take the study medication 
every day. If the women did mention problems, they tended to be practical problems 
associated with taking the medication, primarily the large size of the capsules and 
remembering to take them every day, rather than experiencing doubts or uncertainties about 
the study or the medication. In response to a question about issues she might have had taking 
part in the study, one woman said:
“The massive pills maybe. They were pretty hefty to try and get down.” (ID 3744, 
lines 244-245)
Another said that she had no difficulty swallowing the tablets, but sometimes forgot them:
“The tablets were easy to take. It was actually … trying to remember that I had to 
take them.”(ID 4081, lines 135-136)
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Both these issues may have affected their compliance with the study protocol. Some of the 
women who described experiencing these practical problems with the study medication 
found that developing a daily routine helped:
“I was already taking Pregnacare, so I just took everything together.” (ID 3718, line 
71)
Discussion
This study was carried out in a sub-group of 203 women taking part in a large, multi-centre 
randomised, placebo-controlled trial of the effects of vitamin D supplementation in 
pregnancy on neonatal bone mineral content. Women who entered the study with a lower 
sense of self-efficacy tended to have lower levels of circulating 25(OH)D in early pregnancy, 
though not in late pregnancy in either treatment or control groups. The vitamin D levels of 
these women were more likely to increase over the course of pregnancy than those of 
women with higher self-efficacy, however, presumably because they had lower levels at 
baseline. Responses to the adapted PETS indicated that more than half the women 
experienced problems taking the study medication, but not because they doubted its 
usefulness or were uncertain how to take it. Problems taking the study medication tended to 
be about the size of the capsules or difficulty remembering to take them, but qualitative data 
suggested that women usually found ways of overcoming the practical problems they 
experienced. The data partially support the study hypothesis that having higher self-efficacy 
is associated with better compliance and with factors affecting compliance, which in turn 
improves vitamin D status. Though there was no direct effect of women’s self-efficacy on 
their compliance, women with lower self-efficacy were more likely to experience practical 
problems taking the study medication. Experiencing practical problems was associated with 
poorer compliance with the study protocol which required women to take the medication 
every day; and poorer compliance was associated with lower levels of vitamin D in late 
pregnancy in the treatment group. Qualitative data indicated that the major factors affecting 
compliance were difficulties in remembering to take the study medication every day and in 
swallowing the tablets which came in large capsules.
Strengths and limitations
The women who took part in this study were a highly educated group as were the original 
MAVIDOS study participants with approximately three quarters in both the sub study and 
original study having A level qualifications or above.[2] As a highly educated group, 
participants might be expected to have both higher self-efficacy and 25(OH)D status than the 
general population and therefore not represent the general population of women of child-
bearing age in the UK.[21] Women in this sub-study had, in fact, a comparable mean self-
efficacy score to women in previous studies who had a wider range of educational 
attainment.[22] The high levels of compliance with the study protocol, however, suggest that 
women in this study were highly motivated, and that their responses to taking the 
supplement may not represent those of the general population to routine maternal vitamin D 
supplementation in pregnancy.
Barker et al. Page 7
Osteoporos Int. Author manuscript; available in PMC 2017 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Implications of the study
Women largely complied with the protocol of the trial described in this paper. Those with 
lower self-efficacy experienced more problems, and those who experienced more problems 
took less of the study medication. This finding suggests that improving the self-efficacy of 
participants in clinical trials may indirectly improve compliance. Ensuring compliance is a 
major issue in the success of clinical trials; substantial resources are invested in monitoring 
how well participants adhere to study protocols, because compliance has been shown to have 
significant effects on trial outcomes.[23] It is possible to improve self-efficacy through 
intervention.[24,25] Self-efficacy, or the belief that one is capable of carrying out a specific 
behaviour, is acquired through a combination of watching others or learning about other’s 
experience of achieving these behavioural goals, being told that these goals are possible and 
achievable, past experience of being able to behave in this way, and current physiological or 
mood state.[3] Increasing self-efficacy in order to improve compliance with trial protocols 
could therefore be achieved through an exploratory conversation between participants and 
members of staff recruiting them. Applying these findings to routine vitamin D 
supplementation in pregnancy, conversations to increase self-efficacy for taking pregnancy 
supplements would need to explore the practical problems that the participant might have in 
taking and remembering to take the medication, and to support them to identify ways of 
overcoming them. Some practical problems might relate to the physiological and mood 
changes associated with being pregnant, and examples of ways in which others have 
overcome these difficulties might increase participants’ self-efficacy beliefs about their 
ability to adhere to the protocol.
The reasons women gave for not taking the medication in this study are similar to those 
given by women to explain why they do not take folic acid or iron supplements during 
pregnancy. Women say they forget or that the side effects put them off.[13,14] Though a 
proportion of the women in this study did say they forgot to take the tablets, few were 
worried about medication side-effects or had doubts about the value of the research in which 
they were taking part. This is important to know and encouraging, in the context of making 
recommendations for routine maternal vitamin D supplementation in pregnancy as a public 
health intervention for the purpose of improving maternal and infant health outcomes.
Conclusions
Women’s level of self-efficacy is indirectly associated with their compliance with a trial 
protocol requiring them to take daily vitamin D supplements. Women who had higher self-
efficacy had higher 25(OH)D levels when they came into the trial and experienced fewer 
problems taking the study medication. The more compliant the women in the treatment 
group were with the study protocol, the higher their vitamin D levels in late pregnancy. 
These findings have implications for understanding differences between participants, 
particularly in their level of self-efficacy, and the effect of these differences on trial 
outcomes, and for anticipating responses to recommendations for routine maternal vitamin 
D supplementation in pregnancy.
Barker et al. Page 8
Osteoporos Int. Author manuscript; available in PMC 2017 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Acknowledgements
We thank all our funders for supporting this work (Arthritis Research UK, Medical Research Council, Bupa 
Foundation, National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University 
of Southampton and University Hospital Southampton NHS Foundation Trust, and NIHR Musculoskeletal 
Biomedical Research Unit, University of Oxford) and the women who so kindly gave us their time and took part in 
this study.
Funding: This work was supported by grants from the Arthritis Research UK (17702), Medical Research Council 
(4050502589), Bupa Foundation, National Institute for Health Research (NIHR) Southampton Biomedical 
Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, and 
NIHR Musculoskeletal Biomedical Research Unit, University of Oxford. The work leading to these results was 
supported by the European Union's Seventh Framework Programme (FP7/2007-2013), projects EarlyNutrition and 
ODIN under grant agreements numbers 289346 and 613977. We are extremely grateful to Merck GmbH for the 
kind provision of the Vigantoletten supplement. Merck GmbH had no role in the trial execution, data collection, 
analysis or manuscript preparation. The authors had full access to all study data.
References
1. Harvey N, Dennison E, Cooper C. Osteoporosis: a lifecourse approach. J Bone Miner Res. 2014; 
29(9):1917–1925. DOI: 10.1002/jbmr.2286 [PubMed: 24861883] 
2. Cooper C, Harvey NC, Bishop NJ, Kennedy S, Papageorghiou AT, Schoenmakers I, Fraser R, 
Gandhi SV, Carr A, D'Angelo S, Crozier SR, et al. Maternal gestational vitamin D supplementation 
and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled 
trial. The Lancet Diabetes & Endocrinology. 
3. Bandura, A. Self-efficacy: the exercise of control. W.H.Freeman and Company; New York: 1997. 
4. Ross CE, Wu C. The links between education and health. Am Soc Rev. 1995; 60:719–745.
5. Luszczynska A, Haynes C. Changing nutrition, physical activity and body weight among student 
nurses and midwives: effects of a planning intervention and self-efficacy beliefs. Journal of health 
psychology. 2009; 14(8):1075–1084. [PubMed: 19858328] 
6. Steptoe A, Perkins-Porras L, Rink E, Hilton S, Cappucio FP. Psychological and social predictors of 
changes in fruit and vegetable consumption over 12 months following behavioural and nutrition 
education counseling. Health psychology : official journal of the Division of Health Psychology, 
American Psychological Association. 2004; 23(6):574–581.
7. Harvey NC, Javaid K, Bishop N, Kennedy S, Papageorghiou AT, Fraser R, Gandhi SV, 
Schoenmakers I, Prentice A, Cooper C. MAVIDOS Maternal Vitamin D Osteoporosis Study: study 
protocol for a randomized controlled trial. The MAVIDOS Study Group. Trials. 2012; 13:13.doi: 
10.1186/1745-6215-13-13 [PubMed: 22314083] 
8. Branum AM, Bailey R, Singer BJ. Dietary supplement use and folate status during pregnancy in the 
United States. J Nutr. 2013; 143(4):486–492. DOI: 10.3945/jn.112.169987 [PubMed: 23365107] 
9. Schultink W, van der Ree M, Matulessi P, Gross R. Low compliance with an iron-supplementation 
program: a study among pregnant women in Jakarta, Indonesia. Am J Clin Nutr. 1993; 57(2):135–
139. [PubMed: 8424380] 
10. Khanal V, Adhikari M, Karkee R. Low compliance with iron-folate supplementation among 
postpartum mothers of Nepal: an analysis of Nepal Demographic and Health Survey 2011. Journal 
of community health. 2014; 39(3):606–613. DOI: 10.1007/s10900-013-9806-6 [PubMed: 
24322600] 
11. McGuire M, Cleary B, Sahm L, Murphy DJ. Prevalence and predictors of periconceptional folic 
acid uptake--prospective cohort study in an Irish urban obstetric population. Human reproduction 
(Oxford, England). 2010; 25(2):535–543. DOI: 10.1093/humrep/dep398
12. Mithra P, Unnikrishnan B, Rekha T, Nithin K, Mohan K, Kulkarni V, Kulkarni V, Agarwal D. 
Compliance with iron-folic acid (IFA) therapy among pregnant women in an urban area of south 
India. African health sciences. 2013; 13(4):880–885. DOI: 10.4314/ahs.v13i4.3 [PubMed: 
24940307] 
13. Gebremedhin S, Samuel A, Mamo G, Moges T, Assefa T. Coverage, compliance and factors 
associated with utilization of iron supplementation during pregnancy in eight rural districts of 
Barker et al. Page 9
Osteoporos Int. Author manuscript; available in PMC 2017 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Ethiopia: a cross-sectional study. BMC Public Health. 2014; 14:607.doi: 
10.1186/1471-2458-14-607 [PubMed: 24930036] 
14. Barbour RS, Macleod M, Mires G, Anderson AS. Uptake of folic acid supplements before and 
during pregnancy: focus group analysis of women's views and experiences. Journal of human 
nutrition and dietetics : the official journal of the British Dietetic Association. 2012; 25(2):140–
147. DOI: 10.1111/j.1365-277X.2011.01216.x [PubMed: 22126238] 
15. Shankar AV, Asrilla Z, Kadha JK, Sebayang S, Apriatni M, Sulastri A, Sunarsih E, Shankar AH. 
Programmatic effects of a large-scale multiple-micronutrient supplementation trial in Indonesia: 
using community facilitators as intermediaries for behavior change. Food and nutrition bulletin. 
2009; 30(2 Suppl):S207–214. [PubMed: 20496613] 
16. Harvey NC, Javaid K, Bishop N, Kennedy S, Papageorghiou AT, Fraser R, Gandhi SV, 
Schoenmakers I, Prentice A, Cooper C. MAVIDOS Maternal Vitamin D Osteoporosis Study: study 
protocol for a randomized controlled trial. Trials. 2012; 13(1):13. [PubMed: 22314083] 
17. Schwarzer, R., Jerusalem, M. Generalized Self-Efficacy Scale. Measures in health psychology: A 
user's portfolio. Causal and control beliefs. Weinman, J.Wright, S., Johnston, M., editors. NFER-
Nelson; Windsor, UK: 1995. p. 35-37.
18. Lawrence W, Schlotz W, Crozier S, Skinner TC, Haslam C, Robinson S, Inskip H, Cooper C, 
Barker M. Specific psychological variables predict quality of diet in women of lower, but not 
higher, educational attainment. Appetite. 2011; 56:46–52. [PubMed: 21078352] 
19. Kirby S, Donovan-Hall M, Yardley L. Measuring barriers to adherence: validation of the 
Problematic Experiences of Therapy Scale. Disability and rehabilitation. 2014; 36(22):1924–1929. 
DOI: 10.3109/09638288.2013.876106 [PubMed: 24410171] 
20. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological 
research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986; 51(6):
1173–1182. [PubMed: 3806354] 
21. Leganger A, Kraft P. Control constructs: do they mediate the relation between educational 
attainment and health behaviour? Journal of health psychology. 2003; 8(3):361–372. [PubMed: 
14670214] 
22. Lawrence W, Schlotz W, Crozier S, Skinner TC, Haslam C, Robinson S, Inskip H, Cooper C, 
Barker M. Specific psychological variables predict quality of diet in women of lower, but not 
higher, educational attainment. Appetite. 2011; 56(1):46–52. DOI: 10.1016/j.appet.2010.11.003 
[PubMed: 21078352] 
23. Czobor P, Skolnick P. The Secrets of a Successful Clinical Trial: Compliance, Compliance, and 
Compliance. Molecular Interventions. 2011; 11(2):107–110. DOI: 10.1124/mi.11.2.8 [PubMed: 
21540470] 
24. Michie S, Abraham C, Whittington C, McAteer J, Gupta S. Effective techniques in Healthy Eating 
and Physical Activity Interventions: a meta-regression. Health psychology : official journal of the 
Division of Health Psychology, American Psychological Association. 2009; 28(6):690–701.
25. Prestwich A, Kellar I, Parker R, MacRae S, Learmonth M, Sykes B, Taylor N, Castle H. How can 
self-efficacy be increased? Meta-analysis of dietary interventions. Health Psychol Rev. 2014; 8(3):
270–285. DOI: 10.1080/17437199.2013.813729 [PubMed: 25053214] 
Barker et al. Page 10
Osteoporos Int. Author manuscript; available in PMC 2017 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1. Conceptual model summarising the relationships between self-efficacy, vitamin D at 34 
weeks, compliance with trial protocol, practical problems taking the study medication, 
uncertainty and doubts about taking the medication.
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Table 1
Characteristics of study participants, mean self-efficacy, vitamin D at 14 and 34 weeks, 
percent compliance and numbers(%) of women experiencing problems with taking the 
study medication by treatment group.
Variables N Placebo Cholecalciferol 1000 IU/d Whole group
Age (years), mean (SD) 328 31.1 (5.3) 30.8 (19.3) 31.0 (5.1)
Educational attainment ≥ A level, N (%) 326 122 (75.3) 130 (79.3) 252 (77.3)
14 week Self-efficacy, mean (SD) 328 15.3 (1.9) 15.1 (1.8) 15.2 (1.9)
14 week 25(OH)D (nmol/l), mean (SD) 328 46.5 (16.5) 47.5 (18.2) 47.0 (17.3)
34 week 25(OH)D (nmol/l), mean (SD)* 218 43.4 (19.4) 67.4 (19.7) 55.5 (22.9)
Compliance (%), median (IQR) 216 95.2 (89.6-98.8) 96.5 (90.1-99.2) 96.0 (89.8-98.9)
At least a practical problem, N (%) 202 56 (56.6) 51 (49.5) 107 (53.0)
At least an uncertainty about medication, N (%) 203 15 (15.2) 17 (16.4) 32 (15.8)
At least a doubt about medication, N (%) 203 14 (14.1) 16 (15.4) 30 (14.8)
*p<0.001 for difference between placebo and active group. All other p-values for differences between placebo and active group >0.05
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Table 2
Associations between self-efficacy scores at 14 weeks, PETS and compliance
Placebo Cholecalciferol 1000 IU/d Whole group
Outcomes OR (95% CI) p OR (95% CI) p OR (95% CI) p
Practical problems (Yes vs. No) 0.81 (0.64,1.02) 0.07 0.80 (0.64,1.01) 0.06 0.81 (0.69,0.95) 0.01
Uncertainty (Yes vs. No) 0.90 (0.67,1.22) 0.51 1.00 (0.75,1.33) 0.99 0.95 (0.77,1.17) 0.64
Doubts (Yes vs. No) 0.91 (0.66,1.24) 0.54 0.87 (0.65,1.18) 0.38 0.89 (0.71,1.10) 0.28
r r r
Compliance (SD) 0.04 0.66 0.07 0.49 0.05 0.43
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Table 3
Median (IQR) compliance rate by PETS
Compliance (%) p-value *
Median (IQR)
No practical problems 98.0 (96.4-99.5) <0.001
Practical problems 92.4 (83.7-97.4)
No uncertainties 96.8 (92.1-99.3) 0.02
Uncertainties 90.4 (77.2-98.8)
No doubts 96.8 (91.8-99.3) 0.03
Doubts 91.4 (77.2-98.8)
*Wilcoxon rank-sum test
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Table 4
Association between 25(OH)D (nmol/l) at 34 weeks, self-efficacy at 14 weeks, problems 
taking the study medication and compliance
Placebo Cholecalciferol 1000 IU/d Overall
Predictors β (95% CI) p β (95% CI) p β (95% CI) p
Self-efficacy at 14 weeks (continuous score) -0.3 (-2.2,1.7) 0.80 1.1 (-1.0,3.2) 0.32 -0.3 (-2.0,1.3) 0.68
Practical problems (Yes vs. No) 0.2 (-8.8,9.2) 0.96 -6.2 (-14.7,2.3) 0.15 -5.9 (-13.1,1.3) 0.11
Uncertainty (Yes vs. No) 8.2 (-3.3,19.8) 0.16 -7.2 (-18.5,4.0) 0.21 0.4 (-9.2,10.0) 0.93
Doubts (Yes vs. No) 8.4 (-3.5,20.3) 0.16 -8.3 (-20.2,3.6) 0.17 -0.3 (-10.4,9.7) 0.95
Compliance (%) 0.01 (-0.25,0.28) 0.93 0.54 (0.18,0.89) 0.003 0.29 (0.05,0.54) 0.02
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